Decisive Diagnostics has 24 immortalized human cell lines that have been fully characterized for a number of polymorphisms in pharmacogenomically important genes.  They have all previously been used to make purified DNA for controls in a variety of assays on a range of platforms.  Examples of types of assays include ADME, aCGH, genotyping, and proficiency testing.

Specifications:

• Properly consented and anonymized donors
• Immortalized B-lymphocytes
• 16 male and 7 female cell lines (gender unknown in 1 cell line)
• Varied ethnicity

Polymorphisms:

• 16 distinct CYP2D6 haplotypes.  Metabolism of many drugs including tamoxifen is influenced by CYP2D6 genotype.

• 4 distinct CYP2C19 haplotypes.  Plavix metabolism can be affected by CYP2C19 genotype.

• 8 distinct CYP2C9 haplotypes including a CYP2C9 *2/*3-VKORC1 1173 C>T triple heterozygote.  Together with VKORC1, CYP2C9 genotype influences warfarin dosing.

• 8 distinct VKORC1 haplotypes including a VKORC1 1173 C>T-CYP2C9 *2/*3 triple heterozygote.  Together with CYP2C9, VKORC1 genotype influences warafarin dosing.

• 4 distinct UGT1A1 haplotypes.  Irinotecan metabolism is influenced by UGT1A1 genotype.

• 6 distinct MTHFR haplotypes.  Certain MTHFR genotypes may be associated with risk of miscarriages.

• 8 distinct NAT2 haplotypes.  Many drugs are metabolically activated by NAT2 which also plays a role in detoxifying chemicals in the body.